RecruitingPulmonary Hypertension Due to Lung Diseases and HypoxiaPulmonary HypertensionInterstitial Lung Disease

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Eligible age

18+ yrs

Accepts

All genders

Locations

32 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

Sponsor: United Therapeutics

You may qualify if…

✓ 1. Adults aged 18 years or older
✓ 2. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:
✓ 1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
✓ 2. Autoimmune ILD
✓ 3. Chronic hypersensitivity pneumonitis
✓ 4. Nonspecific interstitial pneumonia
✓ 5. Occupational lung disease
✓ 6. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator

You may not qualify if…

✕ 1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH
✕ a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH.
✕ 2. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.
✕ 3. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.